<?xml version="1.0"?>
<trials subjects="1">
  <Triall>
    <main>
      <UTRN />
      <trial_id>ChiCTR-OOC-17013919</trial_id>
      <utrn />
      <reg_name>ChiCTR</reg_name>
      <date_registration>2017-12-14</date_registration>
      <primary_sponsor>Hebei Yanda Ludaopei Hospital  </primary_sponsor>
      <public_title>Clinical application of immunotherapy to prevent the recurrence of acute leukemia after allogeneic hematopoietic stem cell transplantation</public_title>
      <acronym />
      <scientific_title>Clinical application of immunotherapy to prevent the recurrence of acute leukemia after allogeneic hematopoietic stem cell transplantation</scientific_title>
      <Scientific_acronym />
      <date_enrolment>2017-12-14</date_enrolment>
      <type_enrolment />
      <target_size>Case series:50;</target_size>
      <recruitment_status>Recruiting</recruitment_status>
      <url>http://www.chictr.org.cn/showproj.aspx?proj=23942</url>
      <study_type>Observational study</study_type>
      <study_design>Case series</study_design>
      <phase>Other</phase>
      <hc_freetext>Acute leukemia recurrence after allo-HSCT</hc_freetext>
      <i_freetext>Case series:the NK/CIK therapy;</i_freetext>
      <results_actual_enrolment />
      <results_date_completed />
      <results_url_link />
      <results_summary />
      <results_date_posted />
      <results_date_first_publication />
      <results_baseline_char />
      <results_participant_flow />
      <results_adverse_events />
      <results_outcome_measures />
      <results_url_protocol />
      <results_IPD_plan />
      <results_IPD_description />
    </main>
    <contacts>
      <contact>
        <type>Scientific</type>
        <firstname>Xiaosu Zhou</firstname>
        <middlename />
        <lastname />
        <address>Hebei Yanda Ludaopei Hospital, Sipulan Road, Yanjiao, Hebei, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 13521274760</telephone>
        <email>xiaosu_joe@163.com</email>
        <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
      </contact>
      <contact>
        <type>Public</type>
        <firstname>Peihua Lu</firstname>
        <middlename />
        <lastname />
        <address>Hebei Yanda Ludaopei Hospital, Sipulan Road, Yanjiao, Hebei, China</address>
        <city />
        <country1 />
        <zip />
        <telephone>+86 18611636171</telephone>
        <email>peihua_lu@126.com</email>
        <affiliation>Hebei Yanda Ludaopei Hospital</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>China</country2>
    </countries>
    <criteria>
      <inclusion_criteria>The patients diagnosed as acute leukemia (contains AML and ALL, the United States NCCN 2015.2 standard) after allo-HSCT; Aged 2 to 65 Years; Patients with self-knowledge ability can sign the consent form; Patients or the clients authorized by patients sign the consent form, or pediatric patients' legal guardians sign the consent form and are voluntary to participate in the clinical trials.  </inclusion_criteria>
      <agemin>2</agemin>
      <agemax>65</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Intracranial hypertension or unconsciousness; Symptomatic heart failure or severe cardiac arrhythmia; Respiratory failure; Patients with other types of malignancy; Disseminated intravascular coagulation; Serum creatinine and/or urea nitrogen≥1.5 ×normal; Serum total bilirubin≥1.5 ×normal; Sepsis or other uncontrolled active infection;Uncontrolled diabetes;Severe mental disorder; WHO physical status classification level≥3; Allergic to IL2; Organ transplant recipients; Pregnant or lactating women.  </exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code />
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword />
    </health_condition_keyword>
    <intervention_code>
      <i_code>;</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword />
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>The effective rate of minimal residual disease;The ratio of 2 years-continued complete remission;</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome />
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name />
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id />
        <issuing_authority />
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Hebei Yanda Ludaopei Hospital</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>1990-01-01</approval_date>
        <contact_name>Jingwen Zhang</contact_name>
        <contact_address>Hebei Yanda Ludaopei Hospital, Sipulan Road, Yanjiao, Hebei, China</contact_address>
        <contact_phone />
        <contact_email />
      </ethics_review>
    </ethics_reviews>
  </Triall>
</trials>